EA5

BIOLOGICAL4 trials

Sponsors

Shanghai Lanyi Therapeutics Co., Ltd.

Conditions

Antiphospholipid Syndrome (APS)Generalized Myasthenia Gravis (gMG)Healthy VolunteersPNH - Paroxysmal Nocturnal HemoglobinuriaThrombosis

Phase 1

A Phase Ia Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of EA5 in Healthy Adult Subjects

CompletedNCT07256288

Shanghai Lanyi Therapeutics Co., Ltd.Healthy Volunteers

Start: 2023-05-31End: 2024-08-01Updated: 2025-12-01

A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)

RecruitingNCT07256301

Shanghai Lanyi Therapeutics Co., Ltd.PNH - Paroxysmal Nocturnal Hemoglobinuria

Start: 2024-01-03End: 2026-10-30Target: 24Updated: 2026-05-14

A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis

Active, not recruitingNCT07632976

Shanghai Lanyi Therapeutics Co., Ltd.Antiphospholipid Syndrome (APS), Thrombosis

Start: 2026-05-25End: 2027-12-31Target: 12Updated: 2026-06-08

An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis

Not yet recruitingNCT07818291

Shanghai Lanyi Therapeutics Co., Ltd.Generalized Myasthenia Gravis (gMG)

Start: 2026-09-15End: 2027-12-31Target: 18Updated: 2026-09-14